Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2024-03-01 Epub Date: 2024-03-11 DOI:10.1080/14737140.2024.2328167

Riccardo Camedda, Viviana Frantellizzi, Roberta Danieli, Giuseppe De Vincentis, Luca Filippi

{"title":"Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review.","authors":"Riccardo Camedda, Viviana Frantellizzi, Roberta Danieli, Giuseppe De Vincentis, Luca Filippi","doi":"10.1080/14737140.2024.2328167","DOIUrl":null,"url":null,"abstract":"Introduction: To provide an overview of the available literature data on clinical applications of positron emission tomography (PET) targeting the urokinase-type plasminogen activator receptor in oncology.Methods: A literature search was conducted in PubMed, Web of Science and Scopus databases up to June 2023. The results were presented according to the PRISMA guidelines. The quality of the studies was assessed using the Critical Appraisal Skill Program checklist.Results: Seven papers were selected for final analysis, involving 266 patients with solid tumors who underwent PET with uPAR-ligands. Thematic areas identified include feasibility studies (n = 2) on the safety, pharmacokinetics, and dosimetry of uPAR-targeting radiopharmaceuticals; uPAR-directed imaging in head and neck cancer (n = 2); uPAR PET in prostate cancer (n = 2); and the investigation of uPAR in neuroendocrine neoplasms (n = 1). Six of the seven studies used the radiopharmaceutical [68Ga]Ga-NOTA-AE105 while one study used [64Cu]Cu-DOTA-AE105. The studies showed protocol homogeneity, with static PET imaging at 20 minutes. The quality assessment revealed limitations such as small cohorts and the fact that all studies were performed by a single research group.Conclusions: uPAR-PET appears to be a promising imaging tool in well-selected oncological settings, but it needs to be validated by multicentre collaboration.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"137-145"},"PeriodicalIF":2.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2328167","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: To provide an overview of the available literature data on clinical applications of positron emission tomography (PET) targeting the urokinase-type plasminogen activator receptor in oncology.

Methods: A literature search was conducted in PubMed, Web of Science and Scopus databases up to June 2023. The results were presented according to the PRISMA guidelines. The quality of the studies was assessed using the Critical Appraisal Skill Program checklist.

Results: Seven papers were selected for final analysis, involving 266 patients with solid tumors who underwent PET with uPAR-ligands. Thematic areas identified include feasibility studies (n = 2) on the safety, pharmacokinetics, and dosimetry of uPAR-targeting radiopharmaceuticals; uPAR-directed imaging in head and neck cancer (n = 2); uPAR PET in prostate cancer (n = 2); and the investigation of uPAR in neuroendocrine neoplasms (n = 1). Six of the seven studies used the radiopharmaceutical [⁶⁸Ga]Ga-NOTA-AE105 while one study used [⁶⁴Cu]Cu-DOTA-AE105. The studies showed protocol homogeneity, with static PET imaging at 20 minutes. The quality assessment revealed limitations such as small cohorts and the fact that all studies were performed by a single research group.

Conclusions: uPAR-PET appears to be a promising imaging tool in well-selected oncological settings, but it needs to be validated by multicentre collaboration.

查看原文本刊更多论文

针对癌症中尿激酶纤溶酶原激活物受体（uPAR）的正电子发射计算机断层扫描：系统综述。

简介：目的：概述针对尿激酶型纤溶酶原激活剂受体的正电子发射断层扫描（PET）在肿瘤学中的临床应用：概述针对尿激酶型纤溶酶原激活物受体的正电子发射断层扫描（PET）在肿瘤学中的临床应用：方法：在 PubMed、Web of Science 和 Scopus 数据库中进行文献检索，检索时间截至 2023 年 6 月。结果按照PRISMA指南进行展示。研究质量采用 "批判性评估技能计划 "检查表进行评估：最终分析选取了七篇论文，涉及266名接受uPAR配体PET检查的实体瘤患者。确定的专题领域包括：关于uPAR靶向放射性药物的安全性、药代动力学和剂量学的可行性研究（n = 2）；头颈部癌症的uPAR定向成像（n = 2）；前列腺癌的uPAR PET（n = 2）；以及神经内分泌肿瘤的uPAR研究（n = 1）。七项研究中有六项使用了放射性药物[68Ga]Ga-NOTA-AE105，一项使用了[64Cu]Cu-DOTA-AE105。这些研究的方案具有同质性，均在 20 分钟内进行静态 PET 成像。结论：uPAR-PET似乎是一种很有前途的成像工具，适用于精心挑选的肿瘤环境，但还需要多中心合作进行验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.